FK-960

DB06465ExperimentalSmall molecule

Investigated for use/treatment in dementia, alzheimer's disease, schizophrenia and schizoaffective disorders, and memory loss.

Chemical structure of FK-960
Primary indication
Investigated for use/treatment in dementia, alzheimer's disease, schizophrenia and schizoaffective disorders, and memory loss.Curator reviewed
Formula / weight
C13H16FN3O2 ยท 265.288 g/mol (avg)
Code names
FK-960

Resolves to

Compound
UNII60MMJ100ZXCAS133920-70-4
Structure
InChIKeyXTOKQKWTUYYVAO-UHFFFAOYSA-NSMILESCC(=O)N1CCN(CC1)NC(=O)C1=CC=C(F)C=C1

Which companies are running trials of FK-960, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In